Drug intelligence / Profile preview

botulinum toxin a + ropivacaine

Development stage
Unknown
Modality
Small Molecules
Administration
Intramuscular, Local Infiltration, Perineural, Epidural, Intrathecal, Intradermal, Periarticular
01

Overview

This drug is a combination of botulinum toxin type A and ropivacaine. Botulinum toxin A is a purified neurotoxin protein that blocks acetylcholine release at neuromuscular junctions, causing muscle relaxation and used for various conditions including chronic migraine, muscle spasticity, dystonia, hyperhidrosis, and cosmetic facial wrinkle treatment. Ropivacaine is a local anesthetic that blocks sodium channels in nerve fibers to inhibit nerve impulse conduction, providing regional or local anesthesia for surgery or acute pain management. The combination leverages the neuromuscular blocking effect of botulinum toxin A with the local anesthetic effect of ropivacaine to potentially enhance pain relief and improve clinical outcomes in conditions involving muscle spasm or neuropathic pain. However, co-administration may increase the risk or severity of central nervous system depression.

Other names
Botulinum toxin A associated with ropivacaïneBotulinum toxin A + ropivacaïne
02

Targets

SCN9A (Sodium channel protein type 9 subunit alpha)SCN10A (Sodium channel protein type X alpha subunit)SCN11A (NaV1.9)SNAP25 (Synaptosome-associated protein 25)SV2A (Synaptic vesicle glycoprotein 2A)

Beyond the preview

Go deeper on botulinum toxin a + ropivacaine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on botulinum toxin a + ropivacaine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call